fda changes to tirzepatide FDA's Removal of Semaglutide and the Evolving Decisions: What Compounders Need Know FDA Update: Current Guidelines for

Contact an Orlando medical weight loss provider today to schedule your consultation

And Sodhi noted, "the number just continues to climb when you blow it up to the population level." "When you have more than a million people taking the medication worldwide, that's 10,000 people who could potentially experience gastroparesis according to the incidence rate for semaglutide," he told CNBC

When you superimpose patients with obesity but with low muscle mass and strength, they are at greater risk of adverse outcomes, Batsis says

Most individuals notice weight loss within the first few weeks, with more significant results appearing after three to six months

It is essential to consult a lawyer as soon as adverse effects are noticed to ensure you file within the appropriate timeframe

Early Evidence In the latest GLP-1 study 2025 , orforglipron showed early promise for adults with obesity and those living with type 2 diabetes, especially at the highest evaluated dose